| Company Announcements: (reported by the Company) |
No items found
|
| Elevator Pitch: | At Aegros we believe access to life saving therapeutic plasma drugs is a human right and not a privilege. Our mission is to put the patient first through innovation and we do thanks to the Australian invented HaemaFrac®, Aegros' unique electroseparation process. Our TGA GMP-approved plasma fractionation plant in Macquarie Park, Sydney, manufactures a hyperimmune immunoglobulin product against Covid-19, made from convalescent plasma. Aegros is currently undertaking the final precommercial phase of a clinical trial of our Covid-19 hyperimmune in conjunction with a major Sydney hospital. |
| Category: | Health & biotech |
| URL: | http://www.aegros.com.au |
| Operational Status: | Active |
| ASX Listing Code (if applicable): | |
| Year of Commencement: | 2017 |
| Address: | 5 Eden Park Drive, Macquarie Park, NSW 2113, AU |
| State: | New South Wales |
| Overseas Operations: | No |
| Twitter: | |
| Facebook: | |
| Linkedin: | https://www.linkedin.com/company/aegros |
| Founders: | |
| Awards won: | |
